Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 11/27/24
Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 WeeksZacks Investment Research • 11/18/24
Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in FocusZacks Investment Research • 11/07/24
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/06/24
Countdown to Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPSZacks Investment Research • 11/04/24
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAEPRNewsWire • 11/04/24
WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosisPRNewsWire • 10/21/24
New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific MeetingPRNewsWire • 10/03/24
IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track TagZacks Investment Research • 10/02/24
Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander diseasePRNewsWire • 10/01/24
Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionBenzinga • 09/10/24
Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder ValueSeeking Alpha • 08/11/24
Ionis Pharmaceuticals (IONS) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 08/01/24